High-Caliber Team in Place Throughout Key Geographies Partnerships Established with Experienced European Companies for Customer Care and Logistics BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 1, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it has entered into partnerships with two
BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 5, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the first quarter of 2018 on May
Strong Presence at National Professional Diabetes Congresses in the UK , France and Germany Demonstrates Insulet’s Commitment to the European Diabetes Community BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless
BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at three upcoming investor conferences: This press release
Full Year 2017 Revenue of $463.8 Million , Up 26%, and Gross Margin Up 230 Basis Points Full Year 2018 Expected Revenue Growth of 21% to 25% BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump
Significant Presence at ATTD Congress Demonstrates Insulet’s Future Commitment to the Diabetes Community in Europe Studies Show Exceptional Potential for the Omnipod Horizon System to Maintain Stable Blood Glucose Levels after Specific Meal and Exercise Challenges BILLERICA, Mass.
BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year
Significantly Expands Access to Omnipod and Provides a Pathway to Broader Medicaid Coverage BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco,
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City ,
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the Jefferies 2017 London Healthcare Conference on November 15, 2017 , at
Proceeds for General Corporate Purposes, Including Repurchase of a Portion of Outstanding 2% Convertible Senior Notes Due 2019 and Investment in Manufacturing Operations and International Expansion BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a
BILLERICA, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced its intention to offer, subject to market and other conditions, $300 million
